Clinical Trials
17 trialsNCT00551460 2023-01-10
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
SWOG Cancer Research Network
Phase 2 Completed
NCT00020969 2020-10-05
Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes
CTI BioPharma
Phase 2 Terminated
NCT00274820 2020-07-27
Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Myelofibrosis/Myeloproliferative Disorder
Case Comprehensive Cancer Center
Phase 2 Completed
NCT00006091 2018-11-14
Arsenic Trioxide in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Has Not Responded to Previous Treatment
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT00104806 2018-08-10
Arsenic Trioxide and Cholecalciferol (Vitamin D) in Treating Patients With Myelodysplastic Syndromes
Wake Forest University Health Sciences
Phase 2 Terminated
NCT00118196 2018-05-11
Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
Medical University of South Carolina
Phase 2 Terminated
NCT00528450 2016-01-29
Tretinoin and Arsenic Trioxide With or Without Idarubicin in Treating Patients With Acute Promyelocytic Leukemia
Memorial Sloan Kettering Cancer Center
Phase 2 Terminated
NCT00274781 2015-07-10
Arsenic Trioxide and Gemtuzumab Ozogamicin in Treating Patients With Advanced Myelodysplastic Syndromes
The Cleveland Clinic
Phase 2 Completed
NCT00276601 2014-04-17
Combination Chemotherapy in Treating Patients With Acute Promyelocytic Leukemia
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT00003885 2013-11-06
Arsenic Trioxide in Treating Patients With Recurrent or Refractory Acute Leukemia, Chronic Myeloide Leukemia, Myelodysplasia, Lymphoma, or Myeloma
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00005618 2013-06-21
Arsenic Trioxide in Treating Patients With Relapsed or Refractory Chronic Myelogenous Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT00006008 2013-06-21
Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT00016159 2013-01-16
Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00006090 2012-10-10
Arsenic Trioxide in Treating Patients With Refractory or Relapsed Chronic Lymphocytic Leukemia
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT00006092 2012-09-26
Arsenic Trioxide for Induction Therapy of Adult Patients With Leukemia
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT00005795 2012-06-11
Arsenic Trioxide in Treating Patients With Acute Myeloid Leukemia
Northwestern University
Phase 2 Completed
NCT00250042 2011-09-20
A Phase II Study of Gleevec and Arsenic Trioxide in Patients With CML Who Fail Gleevec
New Mexico Cancer Research Alliance
Phase 2 Completed